Enigma of categorizing COVID-19-related lung parenchymal diseases and management experience with follow-up outcomes in Qatar: a case series

Phool Iqbal; Muhammad Bilal Jamshaid; Aamir Shahzad; Zohaib Yousaf; Saba Nabavi Monfared; Nagham D Sadik; Ibrahim Fawzy Hassan

doi:10.5339/qmj.2022.2

Enigma of categorizing COVID-19-related lung parenchymal diseases and management experience with follow-up outcomes in Qatar: a case series

Qatar Med J. 2022 Feb 18;2022(1):2. doi: 10.5339/qmj.2022.2. eCollection 2022.

Authors

Phool Iqbal^{1

2}, Muhammad Bilal Jamshaid¹, Aamir Shahzad³, Zohaib Yousaf^{1

4}, Saba Nabavi Monfared⁵, Nagham D Sadik¹, Ibrahim Fawzy Hassan⁶

Affiliations

¹ Internal Medicine Department, Hamad Medical Corporation, Doha, Qatar E-mail: dr.phooliqbal89@gmail.com.
² Critical Care Department, Hamad Medical Corporation, Doha, Qatar.
³ Reading Hospital, Tower health, Pennsylvania, USA.
⁴ Dresden International University, Dresden, DEU, Germany.
⁵ Trauma & Emergency Clinical Pharmacist Department, Hamad Medical Corporation, Doha, Qatar.
⁶ Pulmonology and critical care department, Hamad Medical Department, Doha, Qatar.

Abstract

Coronavirus disease 2019 (COVID-19) has become one of the worst global pandemics in recent history. Post-COVID-19 interstitial lung disease is a significant concern in COVID-19 survivors. It is a disabling clinical condition for patients and a burden on the healthcare system. With time and subsequent waves of COVID-19 globally, the post-COVID-19 sequelae of lung diseases can be debilitating. We report cases of three patients with persistent hypoxia post-COVID-19, raising concerns for interstitial lung disease in Qatar. In this report, we shared our experience of the patient's clinical course, complications, and outcomes with post-COVID-19 sequelae of lung parenchymal disease. Patients were followed up during and after treatment until recovery or discharge from the hospital.

Keywords: COVID-19; Medicine; critical care; lung parenchymal diseases.